Trial reportEuropean radiology2012
Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation.
Trial report in European radiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01780766 (Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI: What is the Added Value of Diffusion Weighted Imaging in Diagnosis and Follow-up
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.Clinical and experimental medicine · 2015Pooled it
- Prospective Evaluation of Magnetic Resonance Imaging and [Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma.Journal of hematology & oncology · 2024Article
- Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.Frontiers in immunology · 2022Review
- Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells.Frontiers in immunology · 2022Article
- CD38-specific nanobodies allowFrontiers in immunology · 2022Article
- Minimal residual disease in multiple myeloma: are we there yet?International journal of hematologic oncology · 2020Article
- Radiological imaging in multiple myeloma: review of the state-of-the-art.Neuroradiology · 2020Review
- Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Article
- Article
- Article
- Clinical relevance of PET/CT in patients with newly diagnosed multiple myeloma.International journal of clinical and experimental pathology · 2019Article
- Whole Body MRI and oncology: recent major advances.The British journal of radiology · 2018Review
- Functional and molecular MRI of the bone marrow in multiple myeloma.The British journal of radiology · 2018Review
- Comparison of qualitative and quantitative CT and MRI parameters for monitoring of longitudinal spine involvement in patients with multiple myeloma.Skeletal radiology · 2018Article
- Non-Secretory Myeloma: Ready for a new Definition?Mediterranean journal of hematology and infectious diseases · 2017Review
- MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings.Insights into imaging · 2016Review
- Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.Current hematologic malignancy reports · 2016Review
- Risk Stratification in Multiple Myeloma.Current hematologic malignancy reports · 2016Review
- Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).European journal of nuclear medicine and molecular imaging · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the diagnostic performance of whole-body MRI (WBMRI) with haematological parameters for detecting persistent or relapsing disease in patients with multiple myeloma after stem cell transplantation.
methodsSixty-six WBMRI acquisitions were performed in 33 patients with multiple myeloma at two time points after stem cell transplantation. Extent of disease and inter-test dynamics of intra- and extramedullary myeloma manifestations were compared (kappa statistics) with Uniform Response Criteria, comprising haematological parameters.
resultsUsing data from 66 sequential WBMRI acquisitions in 33 patients, 10 patients (30.3 %) were classified as having progressive disease and 23 (69.7 %) as being in remission. Eight (80 %) of the ten patients with progressive disease revealed intramedullary lesions, and two patients (20 %) had intra- and extramedullary lesions. WBMRI and laboratory tests were concordant in 26/33 (78.8 %) patients. We found an agreement of 51.2 %, 95 % confidence interval 19.8 %-82.6 %, between results from WBMRI and haematological parameters. WBMRI had a sensitivity of 63.6 %, specificity of 86.4 %, PPV of 70.0 %, NPV of 82.6 % and accuracy of 78.8 % for detection of remission.
conclusionsWBMRI allows the detection and exact localisation of intra- and extramedullary myeloma manifestations after stem cell transplantation, but shows only moderate agreement with routinely performed laboratory tests for determination of remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.